Compare Boston Scientific Corporation (BSX) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs FuelCell Energy Inc — how do they compare? Boston Scientific Corporation trades at $43.45 (market cap $66.37B), while FuelCell Energy Inc trades at $19.88 (market cap $1.71B). The key difference: Boston Scientific Corporation is far larger — about 38.8× FuelCell Energy Inc's market cap, and FuelCell Energy Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | FCEL | |
|---|---|---|
Market Cap | $66.37B | $1.71B |
Sector | Health | Industrials |
52-Week High | $108.14 | $36.01 |
52-Week Low | $42.63 | $3.92 |
Enterprise Value | $75.94B | $1.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
FuelCell Energy (FCEL) trades at $19.08, down 9.27% in the last session, as the stock consolidates following recent volatility. The company reported mixed Q1 2026 results with an earnings miss but continues to show revenue growth, with 2025 revenue reaching $158.16M. Technical indicators show a bearish trend with key support at $17-18 levels. Recent developments include a strategic partnership with Siemens to scale clean power solutions and a $225 million stock offering that caused temporary dilution concerns.
FCEL presents a high-risk opportunity with strong growth potential in the fuel cell sector but faces significant fundamental challenges. The company maintains negative profitability metrics and cash burn, though recent partnerships and data center demand provide catalysts. Analyst consensus is mixed with a $20.75 price target representing 8.8% upside, but investors should weigh the growth narrative against persistent losses and dilution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
